Open AccessPembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
Author(s) -
Willemijn S.M.E. Theelen,
Paul Baas
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.06.35
Subject(s) - pembrolizumab , lung cancer , medicine , pd l1 , oncology , cancer research , cancer , immunotherapy